Clinical Trials Sponsored by Amager Hospital

Total 101796 results

Amgen

Active, not recruiting

A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications

Non-squamous Non-small Cell Lung Cancer | Epithelial Ovarian Cancer | Claudin 6-positive Advanced/Metastatic Malignant Solid Tumors

United States, Australia, Switzerland
Amgen

Completed

Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis

Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With | Glucocorticoid-induced Osteoporosis

United States, Bulgaria, Turkey, Italy, Australia, Belgium, Canada, Colombia, India, Mexico, Peru, Russian Federation, Ukraine
Amgen

Terminated

Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

Psoriasis

United States, Belgium, Spain, Czechia, Canada, Italy, Israel, France, Netherlands, Russian Federation
Amgen

Terminated

Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease

Chronic Graft Versus Host Disease cGVHD

United States, Japan, France, Belgium
Amgen

Completed

Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease

Non-alcoholic Fatty Liver Disease

United States
Amgen

Completed

Study of AMG 256 in Adult Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Belgium, Spain, Australia
Amgen

Active, not recruiting

AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)

Small Cell Lung Cancer

United States, Belgium, Austria, Singapore, Taiwan, Japan
Amgen

Completed

A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine

Migraine

United States
Amgen

Completed

Organization of Teratology Information Services (OTIS) Autoimmune Diseases in Pregnancy Project

Pregnancy

United States
Amgen

Terminated

Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus

Active Systemic Lupus Erythematosus

Korea, Republic of, United States, Taiwan, Canada, Spain, Italy, Mexico, Japan, Turkey, Austria, Greece, Colombia, Switzerland, Poland, France, Bulgaria, Hong Kong, Russian Federation, Chile
Amgen

Active, not recruiting

A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201) (FORTITUDE-201)

Squamous-Cell Non-Small-Cell Lung Cancer

France, Belgium, Spain, United States, Taiwan, Korea, Republic of, Japan, Poland
Amgen

Completed

Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants

Healthy Participants

United States
Amgen

Completed

Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity

Obesity

United States
Amgen

Terminated

Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity

Obesity

United States
Amgen

Completed

Multiple Ascending Dose Study of AMG 598 in Adults With Obesity

Obesity

United States
Amgen

Completed

A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications

Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

United States
Amgen

Completed

Study to Determine the Pharmacokinetic (PK) Bioequivalence of ABP 501 and Adalimumab (Humira®) in Healthy Adult Japanese Participants

Healthy Volunteers
Amgen

Completed

Effect of Coadministration of Sotorasib on the Pharmacokinetics of Rosuvastatin in Healthy Participants

Healthy Participants

United States
Amgen

Terminated

Heart Failure Study to Evaluate Vital Signs and Overcome Low Use of Guideline-Directed Therapy by Remote Monitoring (HF-eVOLUTION)

Heart Failure

United States
Amgen

Completed

Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)

Thrombocytopenic Purpura
Amgen

Completed

A Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy Participants

Chronic Graft-versus-host Disease (cGVHD)

United States
Amgen

Completed

A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH (DAHLIA)

Paroxysmal Nocturnal Hemoglobinuria

Spain, Italy, United States, Norway, Czechia, United Kingdom, Slovenia, Netherlands, Turkey, Portugal, Finland, France, Ireland, Sweden
Amgen

Terminated

Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (20170528)

Relapsed/Refractory Acute Myeloid Leukemia (AML)

United States, Korea, Republic of, Australia, Japan, Germany, Canada
Amgen

Completed

Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia

China
Amgen

Terminated

Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta

Osteogenesis Imperfecta (OI)

Canada, Czechia, Spain, United Kingdom, United States, Italy, Hungary, Australia, Belgium, France, Germany, Poland
Amgen

Completed

A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of Life (EMBRACE)

Psoriasis

France, Italy, Spain, United Kingdom, Switzerland, Germany
Amgen

Completed

Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment

Hypercholesterolemia

France, Germany, United States, Czechia, Italy, Australia, Spain, United Kingdom
Amgen

Terminated

Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
Amgen

Completed

Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients (ENDEAVOR)

Multiple Myeloma

Korea, Republic of, Spain, Taiwan, Canada, Australia, Israel, Italy, United States, Singapore, New Zealand, Japan, Thailand, Brazil, United Kingdom, Hungary, Czechia, Romania, Slovakia, France, Germany, Russian Federation, Bulgaria, Belgiu... and more
Amgen

Completed

An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP

Thrombocytopenia | Idiopathic Thrombocytopenic Purpura | Thrombocytopenic Purpura
Amgen

Completed

Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Cancer Patients

Wild-type RAS Metastatic Colorectal Cancer
Amgen

Terminated

Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

Multiple Myeloma | Waldenstrom Macroglobulinemia

United States
Amgen

Completed

P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura

Idiopathic Thrombocytopenic Purpura
Amgen

Completed

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Cancer | Breast Cancer | Breast Neoplasms | Metastatic Cancer | Breast Tumors | Solid Tumors | Oncology | Tumors | Metastases | Locally Recurrent and Metastatic Breast Cancer

United States, Belgium, France
Amgen

Completed

A Study of the Absorption, Metabolism, and Excretion of [14C]-AMG 510 Following a Single Oral Dose in Healthy Male Subjects

Healthy Subjects

United States
Amgen

Completed

PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy

Metastatic Colorectal Cancer
Amgen

Completed

Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.

Bone Metastases
Amgen

Completed

Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders (TAUSSIG)

Severe Familial Hypercholesterolemia

Italy, Czechia, United States, Israel, New Zealand, South Africa, France, Spain, Australia, Belgium, Canada, Netherlands, Hong Kong, Brazil, United Kingdom, Greece, Japan, Lebanon
Amgen

Completed

Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab

Hyperlipidemia | Mixed Dyslipidemia

United States
Amgen

Completed

E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events (EVOLVE)

Chronic Kidney Disease | Secondary Hyperparathyroidism
Amgen

Completed

A Study of AMG 337 in Subjects With Advanced Solid Tumors

Cancer | Advanced Solid Tumors | Oncology | Tumors | Advanced Malignancy | Oncology Patients

United States
Amgen

Completed

Historical Data Analysis of Hematological Remission and Survival in Adults With R/R Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

United States, Czechia, Spain, France, Italy, Germany, United Kingdom, Poland
Amgen

Completed

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects (GAUSS)

Hyperlipidemia

United States, Denmark, Australia, Belgium, Spain, Finland, Sweden, Canada
Amgen

Completed

A Study to Evaluate the Drug-drug Interaction Effect of Rifampin on the Pharmacokinetics of AMG 510 in Healthy Participants

Healthy Participants

United States
Amgen

Completed

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention (STRIVE)

Migraine

United States, Austria, United Kingdom, Belgium, Czechia, Poland, Germany, Netherlands, Turkey, Canada, Finland, Sweden, Slovakia
Amgen

Completed

A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.

Treatment for Prevention of Chronic Migraine

United States, United Kingdom, Poland, Germany, Czechia, Sweden, Canada, Denmark, Finland, Norway
Amgen

Completed

A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention

Treatment for Prevention of Chronic Migraine

United States, United Kingdom, Poland, Germany, Czechia, Sweden, Canada, Denmark, Finland, Norway
Amgen

Completed

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

Migraine

United States, Germany, Denmark, Canada, Finland, Sweden, Norway
Amgen

Completed

Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma (ARROW)

Multiple Myeloma

Canada, Denmark, Finland, France, Italy, Spain, Sweden, United Kingdom, Czechia, Poland, United States, Belgium, Hungary, New Zealand, Australia, Germany, Japan, Greece, Norway, Romania
Amgen

Completed

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a)) (ANITSCHKOW)

Subjects With Hyperlipidemia, Dyslipidemia

Canada, Netherlands, United States

3

Subscribe